In a recent investor call with Pfizer’s leadership and key financial backers, CEO Albert Bourla made it clear that the company has plans to capitalize on its failed COVID vaccines and antiviral drugs for years. “Hopefully, we could be giving it annually and maybe for some groups that are high-risk more often,”Bourla told investorsearlier this year, referring to COVID-19 booster shots and vaccines tailored to specific variants. “Then you have the treatment [Paxlovid] that will, let’s say, resolve the issues of those that are getting the disease,” he continued. According to Kaiser Health News, the company doubled its revenue from 2020 to 2021, bringing in more than $81 billion, and also gained a significant foothold in the American regulatory process. As the world has seen, both the vaccine and the antiviral drug has shown themselves to be ineffective at stopping infections, spread or resolving sickness from the virus.